Co-Diagnostics, Inc.(CODX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Limited institutional coverage
Quality rankings require at least 50 unique 13-F institutional holders to ensure peer comparisons are meaningful. Only 13 institutional filers currently hold this stock.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
CODX Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Co-Diagnostics, Inc. (CODX), a Healthcare sector company. CODX is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least 50 unique 13-f institutional holders to ensure peer comparisons are meaningful. only 13 institutional filers currently hold this stock. Based on the latest XBRL financial filings (Q1 2026), Co-Diagnostics, Inc. reports quarterly revenue of $146.0K, net income of $-9.1M, free cash flow of $-8.0M. Top institutional holders of CODX by reported 13-F value include Private Advisory Group, UBS Group AG, Smartleaf Asset Management, based on the most recent SEC filings. CODX trades on the Nasdaq exchange and files with the SEC under CIK 1692415. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CODX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Co-Diagnostics, Inc. directly from SEC EDGAR.
Revenue
Q1 2026
$146.0K
Net Income
Q1 2026
$-9.1M
Free Cash Flow
Q1 2026
$-8.0M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
-90.9% YoYNet Income
-32.7% YoYOperating Income
-17.5% YoYEPS (Diluted)
-2837.5% YoYTotal Assets
-74.0% YoYTotal Debt
Op. Cash Flow
-31.9% YoY| Metric | FY 2025 | FY 2023 | FY 2022 | FY 2021 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|
| Revenue | $622.5K -90.9% | $6.8M -80.1% | $34.2M -65.0% | $97.9M +45433.7% | $215.0K +438.6% | $39.9K |
| Net Income | $-46.9M -32.7% | $-35.3M -148.2% | $-14.2M -138.8% | $36.7M +691.7% | $-6.2M +1.2% | $-6.3M |
| Operating Income | $-50.2M -17.5% | $-42.7M -58.3% | $-27.0M -158.6% | $46.1M +881.6% | $-5.9M +3.7% | $-6.1M |
| EPS (Diluted) | $-35.25 -2837.5% | $-1.20 -166.7% | $-0.45 -136.6% | $1.23 +432.4% | $-0.37 | — |
| Total Assets | $24.7M -74.0% | $95.3M -22.6% | $123.1M -23.1% | $160.0M +7124.0% | $2.2M +42.6% | $1.6M |
| Total Debt | — | — | — | — | — | $3.8M |
| Operating Cash Flow | $-29.1M -31.9% | $-22.1M -436.2% | $6.6M -84.0% | $41.1M +843.5% | $-5.5M -35.4% | $-4.1M |
Get alerted when CODX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Co-Diagnostics, Inc. including:
Top Institutional Holders of CODX
Private Advisory Group LLC
$77.0K41,387 shUBS Group AG
$13.7K7,368 shSmartleaf Asset Management LLC
$226.00133 shMORGAN STANLEY
$164.0088 shWELLS FARGO & COMPANY/MN
$151.0081 shSBI Securities Co., Ltd.
$108.0058 shHeritage Wealth Advisors
$32.0017 shWestern Wealth Management, LLC
$32.0017 shOSAIC HOLDINGS, INC.
$18.0010 shDANSKE BANK A/S
$13.007 sh
| Fund | Value | Shares |
|---|---|---|
| Private Advisory Group LLC | $77.0K | 41,387 |
| UBS Group AG | $13.7K | 7,368 |
| Smartleaf Asset Management LLC | $226.00 | 133 |
| MORGAN STANLEY | $164.00 | 88 |
| WELLS FARGO & COMPANY/MN | $151.00 | 81 |
| SBI Securities Co., Ltd. | $108.00 | 58 |
| Heritage Wealth Advisors | $32.00 | 17 |
| Western Wealth Management, LLC | $32.00 | 17 |
| OSAIC HOLDINGS, INC. | $18.00 | 10 |
| DANSKE BANK A/S | $13.00 | 7 |
More Healthcare Companies
View all Healthcare →Put CODX on your watchlist
Track score changes the day Co-Diagnostics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is CODX a good stock to buy?
13F Pro's AI-powered analysis of Co-Diagnostics, Inc. (CODX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CODX are available on the CODX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own CODX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CODX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Co-Diagnostics, Inc.'s investment landscape.